Sage Therapeutics, INC Form 4 insider transactions

Michael C. Quirk, Chief Scientific Officer of Sage Therapeutics, has disposed of all his common stock, restricted stock units, and stock options following the company's merger with Supernus Pharmaceuticals, receiving cash and contingent value rights.

Sage Therapeutics Director Jessica Federer disposed of 21,500 stock options as part of the company's merger with Supernus Pharmaceuticals, receiving cash and contingent value rights.

Sage Therapeutics' Chief Operating Officer, Christopher Benecchi, disposed of all his common stock, restricted stock units, and stock options as a result of the company's merger with Supernus Pharmaceuticals, Inc. becoming effective.

A director of Sage Therapeutics, Michael F. Cola, disposed of stock options as part of the company's merger with Supernus Pharmaceuticals, receiving cash and contingent value rights.

A director of Sage Therapeutics, Inc. disposed of common stock and stock options as part of the company's merger with a Supernus Pharmaceuticals subsidiary, receiving cash and contingent value rights.

A director of Sage Therapeutics, George Golumbeski, has reported the disposition of common stock and stock options as a result of the company's merger with Supernus Pharmaceuticals, Inc., effective July 31, 2025.

Sage Therapeutics Director Geno J Germano's stock options were converted into cash and contingent value rights following the completion of the merger with Supernus Pharmaceuticals, Inc.

Sage Therapeutics director James M. Frates reported the disposal of all his common stock and stock options as the company's merger with Supernus Pharmaceuticals became effective on July 31, 2025.

Gregory L. Shiferman, SVP and General Counsel of Sage Therapeutics, disposed of common stock, restricted stock units, and stock options as part of the company's merger with Supernus Pharmaceuticals, receiving cash and contingent value rights.

Sage Therapeutics, Inc. President and CEO Barry E. Greene disposed of over 100,000 common shares and 174,000 stock options as a result of the company's merger with Supernus Pharmaceuticals, Inc. subsidiary, Saphire, Inc., effective July 31, 2025.

Michael C. Quirk, Chief Scientific Officer of Sage Therapeutics, Inc., reported a routine disposition of 113 shares of common stock for tax withholding purposes following the vesting of restricted stock units.

A recent SEC Form 4 filing reveals that Gregory L. Shiferman, Senior Vice President, General Counsel and Secretary of Sage Therapeutics, Inc., engaged in a routine transaction involving the vesting of restricted stock units and subsequent share withholding for tax obligations.

Sage Therapeutics, Inc. director Geno J Germano was granted 21,500 stock options as part of the company's 2024 Equity Incentive Plan and Non-Employee Director Compensation Program.

Sage Therapeutics, Inc. Director George Golumbeski was granted 21,500 stock options with an exercise price of $6.77, vesting over approximately one year.

Sage Therapeutics, Inc. Director James M. Frates was granted 21,500 stock options with an exercise price of $6.77, vesting by June 2026, as part of the company's 2024 Equity Incentive Plan.

Jessica Federer, a Director at Sage Therapeutics, Inc., was granted 21,500 stock options with an exercise price of $6.77, vesting by June 2026.

Sage Therapeutics, Inc. Director Michael F. Cola was granted 21,500 stock options with an exercise price of $6.77 per share, vesting by June 2026.

Sage Therapeutics, Inc. director Elizabeth Barrett was granted 21,500 stock options with an exercise price of $6.77, vesting fully by June 2026, as part of the company's non-employee director compensation program.

Christopher Benecchi, Chief Operating Officer of Sage Therapeutics, reports the acquisition of shares through vested Performance Restricted Stock Units (PSUs) and subsequent disposal of shares to cover tax obligations.

Michael Quirk, Chief Scientific Officer of Sage Therapeutics, reports acquisition and disposal of common stock following the vesting of Performance Restricted Stock Units (PSUs).

Sage Therapeutics CEO Barry E. Greene acquired 19,964 shares of common stock upon the vesting of Performance Restricted Stock Units (PSUs) and disposed of 4,862 shares to cover tax obligations.

Gregory L. Shiferman, a Senior Vice President at Sage Therapeutics, reports the acquisition and disposal of common stock following the vesting of Performance Restricted Stock Units.

Michael Quirk, Chief Scientific Officer and Interim Head of R&D at Sage Therapeutics, reports the acquisition of stock and option awards.

Gregory Shiferman, a Senior Vice President at Sage Therapeutics, reports the withholding of shares to cover tax obligations upon the vesting of restricted stock units.

Gregory Shiferman, a Senior Vice President at Sage Therapeutics, reports the withholding of shares to cover tax obligations upon the vesting of restricted stock units.

Christopher Benecchi, COO of Sage Therapeutics, reports the withholding of shares to cover tax obligations upon the vesting of restricted stock units.

Chief Medical Officer Laura Gault of Sage Therapeutics reports the withholding of shares to cover tax obligations upon vesting of restricted stock units.

Gregory Shiferman, a Senior Vice President at Sage Therapeutics, reports the withholding of shares to cover tax obligations following the vesting of restricted stock units.

Gregory L. Shiferman, a Senior Vice President at Sage Therapeutics, received stock options and restricted stock units as part of an equity incentive plan.

Sage Therapeutics CEO, Barry E. Greene, was granted 174,000 stock options under the company's 2024 Equity Incentive Plan.